MaxCyte, Inc. is a commercial cell engineering company providing platform technologies for the discovery, development, and commercialization of cell and gene therapies. The company's core business centers on its proprietary Flow Electroporation technology, which enables the non-viral delivery of molecules into cells for research and therapeutic applications. Key products include the ExPERT platform, comprising the DTx, ATx, STx, GTx, and VLx instruments, along with associated proprietary disposables and consumables. In January 2025, MaxCyte acquired SeQure Dx, expanding its service offerings to include on-target and off-target gene editing assessment services. The company serves a global customer base that includes large biopharmaceutical companies, biotechnology firms, academic institutions, and government research centers. MaxCyte generates revenue through the sale of instruments and consumables, annual license fees, and strategic partnership agreements that include precommercial milestones and commercial sales-based payments.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage maxcyte.com
Sector Healthcare IR page maxcyte.com
Tags
cell engineering, electroporation, gene therapy, cell therapy, non-viral delivery, gene editing, biopharmaceuticals, research tools, Flow Electroporation, ExPERT, DTx, ATx, STx, GTx, VLx, SeQure Dx, SeQure, GUIDE-seq, ONE-seq, Guide Profiler, SAFER Detection
Press page maxcyte.com/latest-news

Metrics

Valuation  
Market cap $ 124.685M
Market cap (USD) $ 124.685M
P/E -4.83
PEG —
P/BV 0.83
P/S 6.11
P/OCF -5.93
P/FCF -5.81
Dividend yield —
Turnover / mcap —
Returns  
ROE -23.6%
ROI -26.6%
ROIC -23.2%
Profit margin -213.0%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 14
Quality score -62.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue 20.957M 22.215M 19.497M 28.749M 21.571M 0
Net profit -44.63M -41.055M -37.923M -23.571M -19.082M 0
Free cash flow -36.178M -29.261M -25.386M -33.26M -14.514M —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Share price 1.55 4.16 4.7 5.46 10.19 —
Price performance 12m -0.63 -0.11 -0.14 -0.46 — —

Filed figures

Figure Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — 5.17M 6.88M 11.7M 5.78M 4.68M 3.5M
↳ YoY growth +33.0% +69.5% -50.4% -19.0% -25.2%
↳ 5y CAGR -7.5%
Lease liabilities (USD) — — 2.05M 5.68M 16.1M 18.7M 18M 17.9M
Cash and deposits (USD) 11.2M 15.2M 18.8M 47.8M 11.1M 46.5M 27.9M 20.1M
Intangible assets (USD) — — — — — — — 650,000
Right-of-use assets (USD) — — 1.73M 5.69M 9.85M 11.2M 10.8M 10.9M
Cash flow detail
Operating cash flow (USD) — -8.8M -8.78M -10.7M -14.8M -21.7M -27.6M -34.4M
Purchases of property, plant and equipment (USD) — -1.27M -2.07M -3.83M -18.5M -3.7M -1.65M -1.77M
Change in receivables (cash effect) (USD) — 1.59M -1.81M -1.71M -4.78M 5.23M 1.23M 1.15M
Change in inventories (cash effect) (USD) — -1.89M -890,600 -1.41M -3.49M -4.53M 1.36M 575,000
Change in payables (cash effect) (USD) — 1.16M 391,000 2.09M -149,700 3.25M -1.88M -3.72M
Interest paid (cash effect) (USD) — -669,600 -421,400 -420,900 — — — —
Share-based compensation (USD) — 1.75M 2.47M 7.96M 11.8M 14M 13.1M 9.21M
Operating cash flow before change in receivables (USD) — -10.4M -6.97M -8.97M -10M -26.9M -28.8M -35.6M
Free cash flow (OCF - PPE - intangibles) (USD) — -10.1M -10.9M -14.5M -33.3M -25.4M -29.3M -36.2M
Income detail
Research and development expense (USD) — 17.6M 17.7M 15.4M 19.5M 23.8M 22.2M 20.8M
↳ 5y CAGR +4.8% +3.3%
Provision for credit losses (USD) — 54,200 -117,200 — — 171,000 -130,000 35,000
Credit cost ratio (credit losses / average receivables) (%) — — — — — 2.0% 2.5% 0.9%
Reported Mar 22, 2022 Mar 22, 2022 Mar 22, 2022 Mar 22, 2022 Mar 15, 2023 Mar 12, 2024 Mar 11, 2025 Mar 25, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

MaxCyte will host its third quarter 2026 earnings call today, November 10th, at 8:30 a.m. Eastern Time

Third Quarter and Recent Business Highlights:

· Reports total revenue of $10.2 million for the third quarter of 2026, including $8.2 million of core revenue and $2.0 million of SPL Program-related revenue

· Raises Full Year 2026 Total Revenue Guidance to at least $34.5 million, reflecting a projected return to full-year revenue growth

· In July, MaxCyte announced a strategic, multi-platform technology license partnership with Genentech

· MaxCyte today announced the proposed acquisition of Akron Bio, a leading supplier of GMP-grade reagents and ancillary materials, expanding its offering across cell therapy manufacturing and nearly doubling revenue

ROCKVILLE, MD, November 10, 2026 — MaxCyte, Inc. (NASDAQ: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its third quarter ended September 30, 2026 financial results and raised its 2026 total revenue guidance.

Oct 28, 2026

PDF Version

ROCKVILLE, Md., Oct. 28, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics, today announced Company management will participate in three upcoming investor conferences.

  • Stifel 2026 Healthcare Conference Fireside Chat on Wednesday, November 11th at 4:40 PM ET

  • 17thAnnual Craig-Hallum Alpha Select Conference Tuesday, November 17th

  • Stephens Annual Investment Conference Fireside Chat on Wednesday, November 18th at 9:30 AM CT

A live and archived webcast of the events will be available on the “Events” section of the MaxCyte investor relations website at https://investors.maxcyte.com/.

About MaxCyte

At MaxCyte®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQure™ gene editing risk assessment services enable high-performance cell engineering and rigorous evaluation of editing outcomes, supporting confidence in therapeutic development. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we've been advancing cell engineering, shaping the future of medicine.

Learn more at maxcyte.com and follow us on LinkedIn and Bluesky.

MaxCyte Contacts:

Investor Relations Gilmartin Group Erik Abdow [email protected]

Media Contact Oak Street Communications Kristen White [email protected] 415.608.6060

Electroporation Systems

ATX_01

ATx

From small to medium static Electroporation.

STX_01

STx

Transfect up to 20 billion cells with scalable static or Flow Electroporation®.

GTx

GTx

Transfect up to 20 billion cells with our clinically validated and cGMP compliant Flow Electroporation®.

VLX

VLx

For gram scale protein production.

Our Electroporation Technology

Consumables

Processing Assemblies

Processing Assemblies

Achieve the desired scale and throughput with a range of consumable devices.

Accessories & Reagents

Reagents & Supporting Products

Complement your workflow with our flexible electroporation buffer formats and accessories.

Gene Editing Risk Assessment

About SeQure DX™

Screening Assays

Guide Profiler™

Guide Select™

Nomination Assays

ONE-seq

DEUX-seq™

GUIDE-seq™

Confirmation Assays

Amplicon-seq™

SAFER Detection™

Applications

Cell Therapy

Discover scalable engineering to enable safe and potent cell therapies.

Gene Editing

Navigate the complexities of genome engineering with highly efficient delivery.

Protein & Antibody Production

Accelerate biotherapeutic development with transient expression for gram-scale protein production.

Cell Based Assays

Produce assay-ready cells faster with scalable electroporation.

Viral Vector

Transfect adherent or suspension cells to produce a variety of viral vectors.

Vaccine Development

Innovate vaccine research with our adaptable platform for production of recombinant proteins, virus-like particles.

Industries

Cell & Gene Therapy

Partnering with developers to accelerate development and scale cell therapy programs toward clinical success.

Discovery & Translational Research

Accelerating breakthrough discoveries with high-efficiency, reproducible electroporation across cell types.

Bioprocessing

Enabling efficient, reproducible transfection in virtually any cell type for high-yield transient expression and rapid cell line development.

Notifications

Oct 14, 2026

PDF Version

MaxCyte will host its third quarter 2026 earnings conference call on November 10, 2026

ROCKVILLE, Md., Oct. 14, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced preliminary revenue for the third quarter ended September 30, 2026 and raised its 2026 revenue guidance.

Preliminary Third Quarter Revenue

  • Core business revenue of approximately $8.1 million in the third quarter of 2026, an increase of 26% compared to the third quarter of 2025.

  • Strategic Platform License (SPL) Program-related revenue of more than $1.0 million, including milestone revenue of $1.0 million received in the third quarter of 2026. MaxCyte will report royalty revenue with its full financial results on November 10, 2026.

MaxCyte’s third quarter results are preliminary, unaudited and subject to change in connection with the completion of MaxCyte’s quarterly closing process and review procedures. As a result, these preliminary results may differ from the actual results that will be reflected in MaxCyte’s consolidated financial statements for the quarter ended September 30, 2026.

Full Year 2026 Guidance

MaxCyte raises 2026 revenue guidance for core business revenue and SPL Program-related revenue:

  • Full year revenue expected to be approximately $34 million, compared to prior guidance of $30 million to $32 million, consisting of:

  • Core business revenue of approximately $28 million, compared to prior guidance of $25 million to $27 million.

  • SPL Program-related revenue of approximately $6 million for the year, compared to prior guidance of approximately $5 million; SPL Program-related revenue guidance includes both revenue of approximately $4 million from milestone payments and approximately $2 million from commercial royalties.

“Preliminary third quarter and total second half revenue is ahead of our expectations, and we updated our core business revenue guidance to reflect approximately 15% year-over-year growth in the second half of 2026,” said Maher Masoud, President and CEO of MaxCyte. We entered into 2026 with the goal of getting back to growth in the second half and we are very encouraged by our return to double-digit growth, with meaningful outperformance in the third quarter driven by accelerated instrument purchasing from a large customer, which we originally anticipated to occur in the fourth quarter. In addition, we raised our SPL Program-related revenue guidance after recognizing a milestone from one of our SPL partners, our second milestone achieved in 2026. We are now supporting more late-stage clinical programs under our SPL partnerships than ever before with two pivotal trials that have potential for approval as early as next year. Overall, we remain focused on executing on our strategic priorities, strengthening our position as a leading enabling technology partner in cell and gene therapy, and building a foundation for sustainable long-term growth.”

Third Quarter Webcast and Conference Call Details

MaxCyte will host its third quarter 2026 earnings conference call on November 10, 2026, at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the “Events” section of the MaxCyte website at https://investors.maxcyte.com/.

About MaxCyte

At MaxCyte®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQure™ gene editing risk assessment services enable high-performance cell engineering and rigorous evaluation of editing outcomes, supporting confidence in therapeutic development. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we've been advancing cell engineering, shaping the future of medicine.

Learn more at maxcyte.com and follow us on LinkedIn and Bluesky.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements about us and our industry involve substantial known and unknown risks, uncertainties, and assumptions, including those described in Item 1A under the heading "Risk Factors" and elsewhere in our report on Form 10-K, that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans, customer expectations and objectives of management for future operations, are forward-looking statements. Forward-looking statements include, but are not limited to, statements about possible or future results of operations or financial position. In some cases, you can identify forward-looking statements because they contain words such as "may," "might," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "seek," "predict," "future," "project," "potential," "continue," "contemplate," "target," the negative of these words and similar words or expressions. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements. The forward-looking statements contained in this press release, include, without limitation, our full year 2026 revenue, our expectations regarding core business revenue growth in the second half of 2026, statements concerning the following: our expected future growth and success of our business model; the size and growth potential of the markets for our products, and our ability to serve those markets, increase our market share, and achieve and maintain industry leadership; our ability to expand our customer base and enter into additional SPL partnerships; expectations regarding customer-level activities (including the expected advancement of our SPL partners' clinical programs, including Phase 3 trial initiations); the timing and amount of any share repurchases under our share repurchase program; our financial performance and capital requirements; the adequacy of our cash resources and availability of financing on commercially reasonable terms; our expectations regarding general market and economic conditions that may impact investor confidence in the biopharmaceutical industry and affect the amount of capital such investors provide to our current and potential partners; and our use of available capital resources.

These and other risks and uncertainties are described in greater detail in Item 1A , entitled "Risk Factors," in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission, as well as in discussions of potential risks, uncertainties, and other important factors in the other filings that we make with the Securities and Exchange Commission from time to time. These documents are available through the Investor Menu, Financials section, under "SEC Filings" on the Investors page of our website at http://investors.maxcyte.com. Any forward-looking statements in this press release are based on our current beliefs and opinions on the relevant subject based on information available to us as of the date of such press release, and you should not rely on forward-looking statements as predictions of future events. We undertake no obligation to update any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

MaxCyte Contacts:

Investor Relations Gilmartin Group Erik Abdow [email protected]

Media Contact Oak Street Communications Kristen White [email protected] 415.608.6060

Electroporation Systems

ATX_01

ATx

From small to medium static Electroporation.

STX_01

STx

Transfect up to 20 billion cells with scalable static or Flow Electroporation®.

GTx

GTx

Transfect up to 20 billion cells with our clinically validated and cGMP compliant Flow Electroporation®.

VLX

VLx

For gram scale protein production.

Our Electroporation Technology

Consumables

Processing Assemblies

Processing Assemblies

Achieve the desired scale and throughput with a range of consumable devices.

Accessories & Reagents

Reagents & Supporting Products

Complement your workflow with our flexible electroporation buffer formats and accessories.

Gene Editing Risk Assessment

About SeQure DX™

Screening Assays

Guide Profiler™

Guide Select™

Nomination Assays

ONE-seq

DEUX-seq™

GUIDE-seq™

Confirmation Assays

Amplicon-seq™

SAFER Detection™

Applications

Cell Therapy

Discover scalable engineering to enable safe and potent cell therapies.

Gene Editing

Navigate the complexities of genome engineering with highly efficient delivery.

Protein & Antibody Production

Accelerate biotherapeutic development with transient expression for gram-scale protein production.

Cell Based Assays

Produce assay-ready cells faster with scalable electroporation.

Viral Vector

Transfect adherent or suspension cells to produce a variety of viral vectors.

Vaccine Development

Innovate vaccine research with our adaptable platform for production of recombinant proteins, virus-like particles.

Industries

Cell & Gene Therapy

Partnering with developers to accelerate development and scale cell therapy programs toward clinical success.

Discovery & Translational Research

Accelerating breakthrough discoveries with high-efficiency, reproducible electroporation across cell types.

Bioprocessing

Enabling efficient, reproducible transfection in virtually any cell type for high-yield transient expression and rapid cell line development.

Notifications

Prompts

MaxCyte, Inc. (ticker MXCT), listed in United States.